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Conclusions. Accelerated breast hypofractionation treatment allows minimizing the impact of radiation therapy on the patients
quality of life without worsening tolerance and cosmetic results. Its application, however, requires a quality improvement of the
treatments compared to the conventional procedure.
http://dx.doi.org/10.1016/j.rpor.2013.03.073
Accelerated partial breast irradiation by high dose rate brachytherapy
B. de Paula Carranza1, E. Saenz de Urturi Albisu1, S. Moral Sanchez2
1 Instituto Oncológico, Oncologia Radioterapica, Spain
2 Instituto Oncológico, Fisica Medica, Spain
Purpose. Show our experience in accelerated partial breast irradiation (APBI) with HDR brachytherapy, implementation and one
year of treatment, in a selected group of patients with early-stage breast cancer.
Methods and materials. From August 2011 to November 2012, six selected patients with T1 N0, Grade 1–2 ductal breast cancer,
were treated after breast-conserving surgery, with high-dose-rate (HDR) multicatheter brachytherapy. Inclusion criteria were the
most restrictive of ASTRO and ESTRO recommendations. In all cases we performed a CT scan, in which we perform a virtual
dosimetry preimplantation subsequently reproduce the ﬁnal implant. The clinical target volume was drawn with a 1-cm margin
around the surgical clips or seroma, protecting skin and chest wall. All the regions of interest were contoured according to the
International Commission on Radiation Units and Measurements reports 50 and 62 recommendations. Prescribed dose to the
PTV was 34Gy in 3.4Gy fractions in 5 days.
Results. The average size of the PTV was 63.7 cc (50–120), with V100% mean 94.5% V150% mean 26.94 cc, V200% mean 10.69 cc and
D90 average was 105%. DHI (Dosie Homogenity Index) average was 0.62, and COIN (Conformatin Index) average was 0.66. Acute
toxicity: pain in 2 patient, and hematoma in 2 patients. Acute Radiodermitis was not observed. Late toxicity: ﬁbrosis grade1
was observed in 2 patients, and grade 2 in another patient. Slight pigmentation is observed in 2 patients. There have been no
locoregional recurrences or metastases. The aesthetic result was good or very good en 5 patients, and excellent in one.
http://dx.doi.org/10.1016/j.rpor.2013.03.074
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Introduction. Previous studies have demonstrated increased cardiac mortality and morbidity after left-sided breast irradiation.
Different technologies have been developed to minimize this problem. We have analyzed the dosimetry and dose-volume his-
tograms of ten patients diagnosedwith left side breast cancer, stage IA and IB; forwhomweplanned the same two-ﬁeld tangential
treatment with and without active breathing control (ABC) technique.
Objective. To demonstrate dose reduction to left anterior descending coronary artery (LAD) and heart using moderate deep
inspiration breath hold (mDIBH) with ABC.
Methods. Patients underwent scanning free breathing (FB) and then employing active breathing control technique. The mDIBH
treatments were compared with the standard free-breathing for each patient. Dosimetric parameters evaluated: mean heart
dose, heart V50%, mean LAD dose, maximal dose to 0.2 cm3 of the LAD, mean left lung dose and percentage of lung receiving
≥20Gy.Results. The heart V50 decreased to 0% in 8 of 10, the decreasing average was 95%, from a 1.58% of the heart receiving
more than 50Gy in the FB plan to a media of 0.08% with mDIBH (p:0.012); overall, the mean dose to the heart was reduced from
1.989Gy to 0.98Gy (p:0.005), a relative reduction of 50.4%. The mean dose to the LAD was reduced from 14.06Gy with FB to 3.55Gy
using mDIBH (p:0.008), relative reduction of 74.75%. The maximal dose to 0.2 cm3 was reduced from 21.69Gy to 6.36Gy, (p: 0.008),
a reduction of 70.67%. Regarding the left lung, this technique does not seem to show a clear improvement, nor in the V20, nor
in the mean dose.Conclusion. MDIBH with ABC signiﬁcantly reduces heart and LADC doses, what can potentially reduce cardiac
risks. However, lung doses do not show a homogeneous decrease.
http://dx.doi.org/10.1016/j.rpor.2013.03.075
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Introduction. Coronary artery disease is the leading cause of mortality among RT-treated survivors of breast cancer. Signiﬁcantly
increases the risk of 2–3 times compared to the untreated population. The median time to onset varies between 6 and 10 years
